Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: Systematic review of different strategies

Mauri, Gianluca; Pizzutilo, Elio Gregory; Amatu, Alessio; Bencardino, Katia; Palmeri, Laura; Bonazzina, Erica; Tosi, Federica; Stella, Giulia Carlo; Burrafato, Giovanni; Scaglione, Francesco; Marsoni, Silvia; Siravegna, Giulia; Bardelli, Alberto; Siena, Salvatore; Sartore-Bianchi, Andrea

doi:10.1016/j.ctrv.2018.12.006

Cited by 79 publications

(80 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Colon cancer is one of the most common malignancies in the world. The occurrence of colon cancer is a very complex pathogenic process that is controlled by multiple genes and formed in different stages over a long period of time [16][17][18]. With the development of molecular biotechnology, miRNAs related to colon cancer have been discovered one after another.…”

Section: Discussionmentioning

confidence: 99%

Expression and clinical significance of miR-4516 and miR-21-5p in serum of patients with colorectal cancer

Jin

Wang

2020

BMC Cancer

View full text Add to dashboard Cite

Background: This study sought to detect the expression and clinical significance of miR-4516 and miR-21-5p in serum of patients with colorectal cancer. Methods: Bioinformatics methods were used to analyze the expression patterns of miR-4516 and miR-21-5p in colorectal cancer. A total of 80 patients with colorectal cancer, 65 patients with benign colorectal tumors and 50 healthy persons were selected. qRT-PCR was performed to detect the expression levels of serum miR-4516 and miR-21-5p before and after operation or postoperative recurrence. The correlation of miR-4516 and miR-21-5p expression levels with the clinical characteristics and prognosis of colorectal cancer was analyzed, and that with the patient's survival was further examined by Kaplan-Meier analysis. Results: MiR-4516 was poorly expressed in colorectal cancer in the preoperative group, and miR-21-5p was highly expressed. While in the postoperative group, miR-4516 was up-regulated, and miR-21-5p was down-regulated. The low expression of miR-4516 was shown to be related to TNM staging, invasion degree, lymph node metastasis and distant metastasis of the patients. Whereas the high expression of miR-21-5p was proved to be correlated with TNM staging and lymph node metastasis. Kaplan-Meier survival analysis showed that high expression of miR-4516 or low expression of miR-21-5p could contribute to better overall survival. Conclusion: Low miR-4516 or high miR-21-5p could be used as an independent risk factor for prognosis of colorectal cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Expression and clinical significance of miR-4516 and miR-21-5p in serum of patients with colorectal cancer

Jin

Wang

2020

BMC Cancer

View full text Add to dashboard Cite

show abstract

“…Antibodies to EGFR have been shown to confer a survival benefit in the first-, second-or later-line setting for patients with mCRC that is wild type for RAS. However, the benefit of retreatment with such antibodies has been unclear [64]. A recent phase II CRICKET study examined the possibility of rechallenge with antibodies to EGFR in the third-line setting for RAS wild-type mCRC [65].…”

Section: Advantages Of Trastuzumab Deruxtecanmentioning

confidence: 99%

Emerging Targeted Therapies for HER2 Positive Gastric Cancer That Can Overcome Trastuzumab Resistance

Mitani

Kawakami

2020

Cancers

View full text Add to dashboard Cite

Trastuzumab, a monoclonal antibody to human epidermal growth factor receptor 2 (HER2), has improved survival in patients with HER2-positive advanced gastric or gastroesophageal junction cancer (AGC). The inevitable development of resistance to trastuzumab remains a problem, however, with several treatment strategies that have proven effective in breast cancer having failed to show clinical benefit in AGC. In this review, we summarize the mechanisms underlying resistance to HER2-targeted therapy and outline past and current challenges in the treatment of HER2-positive AGC refractory to trastuzumab. We further describe novel agents such as HER2 antibody-drug conjugates that are under development and have shown promising antitumor activity in early studies. basis of these results, trastuzumab was approved for AGC with a high HER2 expression level, and trastuzumab-containing regimens are now a standard option for the first-line treatment of such patients, who accounted for 7% to 17% of all individuals with gastric cancer [3-5]. Derivatives of the ToGA Regimen in the First-Line SettingThe ToGA trial adopted a regimen of cisplatin combined with either 5-fluorouracil (5-FU) or capecitabine, whereas subsequent prospective studies found similar treatment outcomes with regimens containing oxaliplatin or tegafur-gimeracil-oteracil (S-1). In a single-arm, nonrandomized phase II trial (HER2-based strategy in stomach cancer (HERBIS)-1) performed in Japan [6], trastuzumab in combination with S-1 plus cisplatin yielded a confirmed ORR of 68%, with a median OS and a median PFS of 16.0 and 7.8 months, respectively, in HER2-positive AGC patients with measurable lesions, with these results being similar to those of the ToGA trial [2]. Similar efficacy was also apparent in AGC patients without measurable lesions (HERBIS-1B study) [7]. Three phase II studies that assessed the combination of trastuzumab with capecitabine plus oxaliplatin reported a median OS, a median PFS, and an ORR of 13.8 to 21.0 months, 7.1 to 9.8 months, and 46.7% to 67.3%, respectively [8][9][10]. Trastuzumab in combination with S-1 plus oxaliplatin was also shown to provide a similar treatment outcome in a phase II study, with a median OS, a median PFS, and an ORR of 18.1 months, 8.8 months, and 70.7%, respectively [11]. A meta-analysis of data from these trials revealed that S-1 or oxaliplatin can substitute effectively for capecitabine or 5-FU or for cisplatin, respectively [12].Immune checkpoint inhibitors such as antibodies to programmed cell death-1 (PD-1) have recently revolutionized treatment strategies for advanced cancer. Given that trastuzumab was found to stimulate T cell responses [13], the combination of trastuzumab-containing regimens with antibodies to PD-1 is receiving attention. A phase II study including 37 patients with HER2-positive AGC treated in the first-line setting with capecitabine, oxaliplatin, and trastuzumab in combination with the anti-PD-1 antibody pembrolizumab reported an ORR of 83%, with a median PFS of 11.4 months and a median ...

show abstract

“…80,81 The receptors (cancer target proteins) used in the present study are highly expressed and closely involved at various stages of cell proliferations which eventually leads to propagation and invasion of cancer cells. [82][83][84][85] Docking was validated by redocking (Fig. 18).…”

Section: Apoptosis Study By Ao/eb Methodsmentioning

confidence: 99%

“…Docking of compounds 1 and 2 in the active sites of B-RAF kinase, PI3K-gamma receptors, CC chemokine receptor and EGFR kinase domain have been determined since these cancer targets proteins are over-expressed in multiple cancer types such as melanoma, colorectal, thyroid, non-small cell lung cancer, ovarian cancer, prostate cancer, pancreatic cancer, large B cell lymphoma, colon, brain, gastric, breast, bladder cancer and glioblastoma. [82][83][84][85] Moreover, these receptors are attractive targets for the diagnosis and treatment of various cancers. 83,84 The docking studies revealed that compound 2 docked in the active site of all the target proteins with signicant higher docking scores by virtue of hydrogen bonds (B-RAF kinase: CYS532, CYS532; CC chemokine receptor: PHE324, ARG323; EGFR kinase domain: ASP855, LYS745, ARG841 and PI3Kgamma receptors: ASP964, TYR867) and it was further validated by docking their respective standard inhibitors in the active site (Fig.…”

Section: Apoptosis Study By Ao/eb Methodsmentioning

confidence: 99%

“…[82][83][84][85] Moreover, these receptors are attractive targets for the diagnosis and treatment of various cancers. 83,84 The docking studies revealed that compound 2 docked in the active site of all the target proteins with signicant higher docking scores by virtue of hydrogen bonds (B-RAF kinase: CYS532, CYS532; CC chemokine receptor: PHE324, ARG323; EGFR kinase domain: ASP855, LYS745, ARG841 and PI3Kgamma receptors: ASP964, TYR867) and it was further validated by docking their respective standard inhibitors in the active site (Fig. 18).…”

Section: Apoptosis Study By Ao/eb Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Solvent-driven structural topology involving energetically significant intra- and intermolecular chelate ring contacts and anticancer activities of Cu(ii) phenanthroline complexes involving benzoates: experimental and theoretical studies

et al. 2019

View full text Add to dashboard Cite

show abstract

Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: Systematic review of different strategies

Cited by 79 publications

References 67 publications

Expression and clinical significance of miR-4516 and miR-21-5p in serum of patients with colorectal cancer

Expression and clinical significance of miR-4516 and miR-21-5p in serum of patients with colorectal cancer

Emerging Targeted Therapies for HER2 Positive Gastric Cancer That Can Overcome Trastuzumab Resistance

Solvent-driven structural topology involving energetically significant intra- and intermolecular chelate ring contacts and anticancer activities of Cu(ii) phenanthroline complexes involving benzoates: experimental and theoretical studies

Contact Info

Product

Resources

About